Showing 551-560 of 9358 results for "".
- FDA Clears CellFX from Pulse Bioscienceshttps://practicaldermatology.com/news/fda-clears-cellfx-from-pulse-biosciences/2460682/The FDA has cleared the CellFX® System from Pulse Biosciences, Inc. for dermatologic procedures requiring ablation and resurfacing of the skin, and a controlled commercial launch will soon begin in the US with a select group of leaders in aesthetic dermatology. The CellFX System is a multi-applica…
- ADCS Acquires Montgomery Dermatology; Catawba Research Enters Partnershiphttps://practicaldermatology.com/news/adcs-acquires-montgomery-dermatology-catawba-research-enters-partnership/2460565/Advanced Dermatology and Cosmetic Surgery (ADCS), the largest dermatology practice in the US, has acquired Dermatology Associates of Montgomery, a leading dermatology practice based in the Southeast. Bundy Group served as exclusive financial advisor to Dr. Steve Maddox, owner of Dermatology Associa…
- Industry Responds to COVID-19: BTL Gives Backhttps://practicaldermatology.com/news/coping-with-covid-19-btl-gives-back/2460542/BTL is revamping several of their manufacturing facilities to provide face masks and ventilators to the medical community. As of September 2020, BTL's European manufacturing facilities have been producing ventilators and masks including FFP2 (European Equivalent to N-95) flat-fit respirator mas…
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Prescription Drug User Fee Agreement (PDUFA VI), the …
- Water's Edge Dermatology Acquires Coast Dermatologyhttps://practicaldermatology.com/news/waters-edge-dermatology-acquires-coast-dermatology/2460055/Water's Edge Dermatology, a provider of comprehensive dermatology services through 37 Florida locations, has acquired a controlling interest in Coast Dermatology, a medical/cosmetic dermatology practice in Venice, Florida. Terms of the transaction were not disclosed. This transaction follows the W…
- Crown Labs Adds to Portfolio with Acquisition of Keri from GSKhttps://practicaldermatology.com/news/crown-labs-adds-to-portfolio-with-acquisition-of-keri-from-gsk/2460017/Crown Laboratories, Inc. acquired the North American rights for Keri from GlaxoSmithKline (GSK). The acquisition of Keri from GSK marks the sixth product from GSK that Crown has acquired in the past five months. “Acquiring the Keri brand supports Crown’s objective of providing its customers with …
- AAD Announces 2019 Election Resultshttps://practicaldermatology.com/news/aad-announces-2019-election-results/2459967/The votes have been counted in the 2019 AAD Election, and the following candidates will take office at the conclusion of the 2020 Annual Meeting in Denver, Colorado on March 24, 2020. The President-Elect is Kenneth J. Tomecki, MD, FAAD and the Vice President-Elect is Neal Bhatia, MD, FAAD, who is …
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the excel …
- Colorescience Receives Patent for Even Up Clinical Pigment Corrector Formulationhttps://practicaldermatology.com/news/colorescience-receives-patent-for-even-up-clinical-pigment-corrector-formulation/2457687/The US Patent and Trademark Office (USPTO) has granted a patent for Colorescience’s LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment Perfector®. The now patented…
- Encore Dermatology Launches Impoyz Cream 0.025%, a Newly Formulated High-Potency Topical Corticosteroidhttps://practicaldermatology.com/news/encore-dermatology-launches-impoyz-cream-0025-a-newly-formulated-high-potency-topical-corticosteroid/2457787/Encore Dermatology Inc. launched its new topical product, Impoyz Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate. “Psoriasis p…